Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423862 | 0.87 | CYP2C19 (0.62) | CYP2C19RBP4DPP4DPP8DPP9 | |
| SCHEMBL12182097 | 0.80 | DPP4 (0.39) | CYP2C19RBP4DPP4DPP8DPP9 | |
| SCHEMBL14970433 | 0.77 | RBP4 (0.53) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL34469152 | 0.76 | DPP4 (0.39) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL17232727 | 0.75 | CYP2C19 (0.55) | CYP2C19RBP4KDM4ECHRNA7 | |
| SCHEMBL5644483 | 0.75 | DPP4 (0.50) | RBP4DPP4DPP8DPP9DPP7 | |
| SCHEMBL19454319 | 0.74 | CYP2C19 (0.43) | CYP2C19RBP4KDM4E | |
| SCHEMBL12811132 | 0.73 | CYP2C19 (0.49) | CYP2C19RBP4KDM4ECHRNA7 | |
| SCHEMBL16572331 | 0.73 | CYP2C19 (0.49) | CYP2C19RBP4KDM4ECHRNA7 | |
| SCHEMBL1424003 | 0.72 | DPP4 (0.46) | RBP4DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| EP-2571876-B1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| EP-2086643-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | Glaxo Group Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008113795-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113795-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008053031-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053031-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | CYP2C19 4852/4885RBP4 3689/4885DPP4 2232/4885 |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM2, GRIN3A | CYP2C19 1586/4885RBP4 2599/4885DPP4 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.